Decreasing the levels of immunosuppressive factors that limit T-cell response in the tumor microenvironment, or improving the trafficking of activated, tumor-specific T cells to tumors, may broaden and deepen antitumor responses to PD1/PDL1 inhibition. Here, CD274 is linked to neoplasm.